1 month Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Buy” by BrokeragesMarketBeat
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have received a consensus rating of “Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hol…
X